Amniotics AB (publ) (AMNI.ST)
SEK 0.01
(5.88%)
SEK 0.01
(5.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -27.14 Million SEK | 39.5% |
| 2022 | -44.86 Million SEK | 12.82% |
| 2021 | -51.46 Million SEK | -74.99% |
| 2020 | -29.4 Million SEK | -189.84% |
| 2019 | -10.14 Million SEK | -43.14% |
| 2018 | -1335.00 SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | -5.55 Million SEK | 8.92% |
| 2023 Q4 | -7.04 Million SEK | -26.77% |
| 2023 Q1 | -10.81 Million SEK | -23.01% |
| 2023 Q2 | -6.09 Million SEK | 43.62% |
| 2023 FY | - SEK | 28.49% |
| 2022 Q3 | -15.33 Million SEK | -50.94% |
| 2022 Q4 | -8.79 Million SEK | 42.65% |
| 2022 Q2 | -10.15 Million SEK | 4.02% |
| 2022 Q1 | -10.58 Million SEK | 14.48% |
| 2022 FY | - SEK | 12.82% |
| 2021 Q1 | -12.07 Million SEK | 11.39% |
| 2021 Q4 | -12.37 Million SEK | -26.55% |
| 2021 Q3 | -9.77 Million SEK | 43.28% |
| 2021 Q2 | -17.23 Million SEK | -42.77% |
| 2021 FY | - SEK | -74.99% |
| 2020 FY | - SEK | -189.84% |
| 2020 Q4 | -13.62 Million SEK | -150.66% |
| 2020 Q3 | -5.43 Million SEK | -33.89% |
| 2020 Q2 | -4.06 Million SEK | 26.02% |
| 2020 Q1 | -5.48 Million SEK | 0.0% |
| 2019 FY | - SEK | -43.14% |
| 2018 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 92.62% |
| Camurus AB (publ) | 562.54 Million SEK | 104.825% |
| Mendus AB (publ) | -97.84 Million SEK | 72.259% |
| Lipum AB (publ) | -37.11 Million SEK | 26.876% |
| NextCell Pharma AB | -40.98 Million SEK | 33.774% |
| Simris Alg AB (publ) | -22.36 Million SEK | -21.375% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -58.875% |
| Active Biotech AB (publ) | -43.88 Million SEK | 38.153% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -90.919% |
| BioArctic AB (publ) | 275.38 Million SEK | 109.856% |
| Cantargia AB (publ) | -284.31 Million SEK | 90.453% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -38.633% |
| CombiGene AB (publ) | -35.33 Million SEK | 23.186% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 80.729% |
| Genovis AB (publ.) | 64.57 Million SEK | 142.035% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 76.378% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 26.688% |
| Intervacc AB (publ) | -68.98 Million SEK | 60.651% |
| Kancera AB (publ) | -61.88 Million SEK | 56.142% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -1.344% |
| LIDDS AB (publ) | -39.67 Million SEK | 31.578% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -124.248% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 186.432% |
| OncoZenge AB (publ) | 7.26 Million SEK | 473.562% |
| Saniona AB (publ) | -69.69 Million SEK | 61.055% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 91.45% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 90.376% |
| Xintela AB (publ) | -53.47 Million SEK | 49.238% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 84.016% |
| Ziccum AB (publ) | -20.34 Million SEK | -33.433% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1357250.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 88.577% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -1204.952% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -102.092% |
| Corline Biomedical AB | -1.69 Million SEK | -1505.145% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 84.34% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 50.474% |
| Aptahem AB (publ) | -10 Million SEK | -171.18% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 335.025% |
| Fluicell AB (publ) | -25.91 Million SEK | -4.743% |
| Biovica International AB (publ) | -119.5 Million SEK | 77.287% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 35.717% |
| AcouSort AB (publ) | -16.7 Million SEK | -62.504% |
| Abliva AB (publ) | -93.6 Million SEK | 71.004% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 91.494% |
| 2cureX AB (publ) | -35.13 Million SEK | 22.749% |
| I-Tech AB | 30.34 Million SEK | 189.448% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 96.201% |
| Cyxone AB (publ) | -20.41 Million SEK | -32.963% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 73.507% |
| Biosergen AB | 228 Thousand SEK | 12004.825% |
| Nanologica AB (publ) | -62.11 Million SEK | 56.305% |
| SynAct Pharma AB | -222.7 Million SEK | 87.812% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 38.116% |
| BioInvent International AB (publ) | -312.7 Million SEK | 91.32% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 8872.417% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 64727.729% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 88.281% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -208.006% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 74.997% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -136.664% |